Tipiracil
Structural formula | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||
Surname | Tipiracil | |||||||||||||||
other names |
|
|||||||||||||||
Molecular formula | C 9 H 11 ClN 4 O 2 | |||||||||||||||
Brief description |
white solid (hydrochloride) |
|||||||||||||||
External identifiers / databases | ||||||||||||||||
|
||||||||||||||||
properties | ||||||||||||||||
Molar mass | 242,67 g · mol -1 | |||||||||||||||
solubility |
soluble in water (hydrochloride) |
|||||||||||||||
safety instructions | ||||||||||||||||
|
||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Tipiracil is a synthetically produced chemical compound from the group of uracil derivatives (“pyrimidinediones”) and an analogue of the nucleobase thymine . The compound is used in combination with trifluridine in chemotherapy for the treatment of colorectal cancer . As an inhibitor of the enzyme thymidine phosphorylase , tipiracil prevents the otherwise too rapid breakdown of trifluridine. On April 25, 2016, the European Commission approved trifluridine / tipiracil for the treatment of adult patients with metastatic colorectal cancer for whom previously available therapy options have been exhausted or for patients for whom these treatments are not suitable.
properties
The hydrochloride salt of tipiracil is used medicinally. Tipiracil hydrochloride is a crystalline, non-hygroscopic powder that dissolves easily in water and in buffer solutions in the range of pH 1–12.
Trade name
Fixed combination of Tipiracil with trifluridine: Lonsurf (pharmaceutical company: Servier ).
Web links
Public Assessment Report (EPAR) of the European Medicines Agency (EMA) for: Lonsurf
Individual evidence
- ↑ a b Data sheet Tipiracil hydrochloride ≥98% (HPLC) from Sigma-Aldrich , accessed on June 27, 2016 ( PDF ).
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
- ↑ a b Taiho's Lonsurf (R) (trifluridine and tipiracil hydrochloride) Tablets Approved In Japan for Treatment of Advanced Metastatic Colorectal Cancer . March 24, 2014.
- ↑ Tanaka, K. Sakamoto, H. Okabe, A. Fujioka, K. Yamamura, F. Nakagawa, H. Nagase, T. Yokogawa, K. Oguchi, K. Ishida, A. Osada, H. Kazuno, Y. Yamada , K. Matsuo: Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models . In: Oncology Reports . 32, No. 6, 2014, pp. 2319–26. doi : 10.3892 / or.2014.3487 . PMID 25230742 . PMC 4240496 (free full text).
- ↑ oncotrends.de: Trifluridine / Tipiracil approved for previously treated patients with metastatic colorectal cancer in Europe - Oncotrends , accessed on June 27, 2016.